Lance Feller, MD
Dr. Lance Feller is a board-certified rheumatologist with dual fellowship training in adult and pediatric rheumatology. His research and clinical experience has included a variety of health conditions including juvenile arthritis, lupus, and scleroderma. He has a special interest in caring for adults with pediatric rheumatology conditions and helping to transition juveniles with rheumatic diseases from pediatric care into an adult practice.
Dr. Feller earned his bachelor’s degree in biochemistry and cell biology, as well as psychology, from the University of California, San Diego. He then went on to receive his M.D. degree from St. George’s University School of Medicine in Grenada, West Indies, followed by a residency in internal medicine and pediatrics at Newark Beth Israel Medical Center in New Jersey. He completed both adult and pediatric rheumatology fellowships at the Saint Louis University School of Medicine in Missouri.
Prior to joining UCF, Dr Feller was in practice in Maine. From 2017 to 2018 he served as a volunteer Clinical Assistant Professor at the University of Vermont College of Medicine.
Dr. Feller is highly skilled in the fields of adult and pediatric rheumatology. He is also interested in rheumatoid arthritis, vasculitis, systemic sclerosis, and uveitis.
Previous research includes the use of a novel biomarker in pediatric arthritis (14-3-3 eta). He remains active in clinical research, with a special interest in pediatric disease that also affect adults including inflammatory arthritis, systemic sclerosis and dermatomyositis. He was among a group of pediatric rheumatologists who in 2015 completed the design of a national consensus treatment protocol for juvenile dermatomyositis, which is now being used for nationwide study on this disease.
He is a Fellow of the American College of Rheumatology (FACR), a member of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and a member of the National Med-Peds Residents’ Association (NMPRA).
- Spencer et al. Biologic Therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatric Rheumatology (2017) 15:50. DOI 10.1186/s12969-017-0174-0
- Dalrymple AM, Tuttle P IV, Feller L, Zhukov OS, Lagier RJ, Bridgforth R, Williams GJ, Popov JM, Naides SJ, Moore T. 14-3-3η (eta) Protein in Juvenile Idiopathic Arthritis (JIA) Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). (Presented ACR/ARHP Annual Scientific Meeting, San Diego, Nov 2017).
- Dalrymple A, Tuttle P IV, Feller L, Zhukov OS, Lagier RJ, Bridgforth R, Williams GJ, Popov J, Naides SJ, Moore T. 14-3-3π(eta) Protein in Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). (Presented Pediatric Rheumatology Symposium (PRSYM), Houston, May 2017).
- Feller L, Dalrymple AM, Tuttle P IV, Syed RH, Pepmueller P, Moore T. Examination of the Clinical Significance of 14-3-3 Eta in Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). (Presented ACR/ARHP Annual Scientific Meeting, San Francisco, Nov 2015).
- Feller L, Tuttle P IV, Dalrymple AM, Bathula S, Temprano K, Syed RH, Bandlamudi R, Coulson K, Pepmueller P, Moore T. Single Academic Center Experience with 14-3-3 Eta in the Evaluation of Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). (Presented at ACR/ARHP Annual Scientific Meeting, San Francisco, Nov 2015).
- Feller LS, Tuttle PV, Moore TL: Clinical utility of 14-3-3n in the evaluation of inflammatory arthritis. Arthritis Rheum 66:S170, 2014 (Presented American College of Rheumatology, Boston, MA, November 2014).
- Feller L, Gilliam B, Cleland E, Syed RH, Pepmueller, PH, Moore TL: Demonstration of antibodies to multiple citrullinated epitopes in the sera of patients with juvenile idiopathic arthritis. Arthritis Rheum 66:S154, 2014 (Presented Pediatric Rheumatology Symposium, Orlando, FL, April 2014).
- Moore TL, Gilliam BE, Crespo-Pagnussat S, Feller L, Chauhan AK: Measurement and evaluation of isotypes of anti-citrullinated fibrinogen and anti-citrullinated α-enolase antibodies in juvenile idiopathic arthritis. Clin Exp Rheumatol 32:740-746, 2014.
- Gilliam B, Feller L, Moore TL: IgG anti-cyclic citrullinated peptide antibodies are associated with joint destruction in juvenile idiopathic arthritis patients. Arthritis Rheum 65:S937, 2013 (Presented American College of Rheumatology, San Diego, CA, October 2013).